Andy Silvernail
Analyst · UBS
Thank you Bill. Good morning everybody. I appreciate you joining us to discuss our second quarter results. Let me start with a brief overview. Look, we had another outstanding quarter. As a matter of fact, I would say in my seven years as CEO, it's the strongest overall quarter we have had and resulted in a very strong first half of the year. Just about every market that we have has shown solid growth and the economy we are in strong despite what we are seeing with global trade. I will provide more details on market conditions and geographies in a minute. Strong execution and continued healthy market conditions drove another record quarter for IDEX. After achieving all-time highs in orders, sales, operating income and EPS in the first quarter, we topped that this quarter and once again hit all-time highs in each of these categories. I am very pleased with our record second quarter and our first half operating results. I will go into more detail shortly, but let me give just a quick overview and some highlights here. Orders were up 9% overall, 8% organically. Sales were up 11%, up 9% organically. Adjusted operating margin was up 180 basis points to 23.6%. Adjusted EPS was $1.40, up $0.32, or 30%. And free cash flow was $110 million, up 40%. Of all the positive numbers in the quarterly results, I am most proud of the team's sustained outperformance on organic growth. The high single digit growth rates for both orders and sales driven by solid growth across all three segments is truly outstanding. Overall, we delivered terrific operating performance. Before I go through more specific details on financial results, let me add that I am excited that we just announced the acquisition of Finger Lakes Instrumentation, which will fill strategic gap and a nice complement in our IDEX health and science portfolio. I am also thrilled with the asset purchase of Phantom Controls that we made in June. These acquisitions will be a nice add to our portfolio. Finally, we continue to live the IDEX difference daily. Great teams embracing 8020 are driven by customer obsession. It's nice to watch a culture of the company embrace our initiatives and show up in our financial results. Now let me take a minute to talk about the markets that we play in and the regions we serve. In industrial, industrial production momentum continues. Day rates for our book and bill business remains at high levels and we see increased project activity converting to orders. In scientific, fluidics and optics, demand within life sciences remains positive and we continue to have a really, really nice performance overall. Energy, we have had a rebound in this market. Midstream oil and gas has picked up and upstream remains strong. In semicon, the global markets have remained strong, really all year and we look forward to that strength continuing. In agriculture, the markets continued to perform and the OEMs have affirmed the outlook for the balance of the year. We do have some concern here relative to trade but we will have to monitor that going forward. In the municipal markets, the markets remained strong. New product development in water has been a really nice benefit for us and emerging markets have done well. Now let's look at the geographies. Overall, things are going well for us in North America. Europe continues to be solid. And in Asia, in both China and India, we see things going very well. In summary, what we saw begin to experience in 2017 has accelerated in 2018. Once again, I would like to talk about for a minute with what we are seen with tariffs. Based on the enacted tariffs, our best estimate is that we are going to see $4 million to $6 million of impact in 2018. We continue to look at all of our options including pricing and alternative sourcing strategies and we have done a really nice job of overall balancing the overall margin impact to the business. Let me take a second and talk about inflation. We are starting to see the higher impact from inflation, but we have been very successful in mitigating the uptick through productivity and price realization. With that said, inflation remains a concern and the team is doing a very, very well, a very, very good job of monitoring this impact on a go forward basis. Let's turn to capital deployment. I would like to take a minute to recap our capital deployment strategy. As always, organic growth remains our number one focus and the team is dedicated to our overall targeted organic growth and new product development initiatives. This is evidenced by our outstanding organic order and revenue performance. With M&A, it remains a priority for us and we continue to evaluate a lot of opportunities. We are going to remain disciplined and focused on delivering the best possible returns to our shareholders. Our balance sheet is strong and when the right deals come along, we will capitalize on it. Speaking of the right deals, I am excited to welcome both been Phantom Controls and Finger Lakes to the family. The assets of Phantom Controls will match nicely with our current fire suppression business and help accelerate our waterflow strategy. And on Monday, we expanded our health and science portfolio by adding Finger Lakes Instrumentation. This will be a nice add to our overall fluidics and optical business. We will work to quickly integrate both of these acquisitions and bring them into the family in the short order. In terms of share repurchases, during the quarter, we deployed approximately the $20 million to repurchase 147,000 shares of stock. We remain committed to our strategy of repurchasing shares when it will create long-term shareholder value. In the second quarter, the Board approved a $0.06 increase in our quarterly dividend, which equated to a 16% increase. This resulted in a $33 million dividend payout to our shareholders in the quarter. All right. Let me turn now to our results here in the second quarter. I am on slide four. Q2 orders of $639 million were up 9% overall and 8% organically. Again, the strong order growth from all three segments, the strength in the first half orders provides us the confidence for the second half. Q2 revenue of $634 million was up 11% overall and 9% organically, driven by positive results in all three segments. FMT was up 10%, HST was up 8% and FSD was also up 8%. We built $5 million of backlog in the quarter on top of the $20 million that we built in the first quarter. We expanded Q2 gross margins by 50 basis points to 45.3%, primarily due to production efficiencies and volume leverage, partially offset by the investments in engineering. Q2 operating income was $149.8 million, adjusted for approximately $2 million of restructuring expenses. That was up 20% compared to the prior period. Q2 operating margin adjusted for the $2 million restructuring was 23.6%, up 180 basis points year-over-year. Similar to the first quarter, the majority of the restructuring expenses were within HST and are associated with our investment in the new optics center of excellence in Rochester, New York. Consolidated operate margin was also impacted by higher corporate costs, which was mainly due to $2.2 million stamp duty in Switzerland associated with the restructuring of an intercompany loan. Q2 net income was $107 million resulting in EPS of $1.38. Excluding the restructuring expenses, EPS was $1.40, an increase of $0.32, or 30% over last year. Our Q2 effective tax rate was 21.7%, which is lower than the 26.1% in the prior period. This was mainly due to the enactment of the 2017 tax reform at the end of last year. The 21.7% second quarter ETR was 80 basis points favorable to our previously guided amount. This was driven by continuous effort to modify our tax strategies and to the tax reform. The positive EPS impact of our lower ETR versus our guide was basically offset by the same tax I mentioned earlier. Overall, we had $0.09 operational beat versus the midpoint of our guide. Free cash flow was $110 million, 101% of adjusted net income and up over 40% from last year. And finally, flow through was another great story, over 40% of sales. In regards to our balance sheet, it's very healthy. We have gross debt of 1.4 times, net debt of 0.6 times and well over $1 billion in capital to deploy. Let me now turn to the segment discussion. I am on slide five, starting with fluid metering. FMT continues to put up strong numbers, both from an order and revenue perspective. Q2 orders were up 6% overall, 7% organically. Q2 sales up 10% overall and organically. Op margin adjusted for restructuring was 29.5%, up 240 basis points over the prior year, mainly due to volume leverage and productivity. The ag business, as I mentioned, continues to be strong and we are watching out for the impact of tariffs. In industrial fluids, the pump business is very impressive. It had record orders of sales. The U.S. distribution market is solid and day rates for book and ship continue to improve. Increased oil prices are driving continued strength in oil and gas as well as the business for our LACT. Valves, targeted growth initiatives in Europe and China have performed well in the quarter. And in water, we are well-positioned driven by new products. In energy, new product development is progressing and expected to provide future opportunities and the project funnel is solid for the back half of the year. Let's move on health and science. I am on slide six. I am very pleased with the health and science results in the quarter. Q2 revenues were up 11% overall, up 8% organically. Orders were up 5% overall, but only 2% organically. HST had a tough comp due to some very large project wins last year in MPT. Just to remember, HST orders last year were up 11%. Excluding restructuring expenses, adjusted operating margin was 23.6%, an increase of 100 basis points in the quarter mainly due to higher volume and productivity. As I stated on our last call, 23% to 24% operating margin is much closer to what I expect in the segment to be performing and I would like to commend the team once again for the improved performance. In life science and optics, the IVD/BIO end-markets continue to overperform. The recent acquisition of Finger Lakes Instrumentation will continue our expansion within this market. We are encouraged to add these technologies that Finger Lakes will bring and excited to bring them into our fluidics, microfluidics and optical illumination and detection business. In sealing solutions, the semicon market remains very robust on a global basis. Transportation and oil and gas are also doing well. In MPT, the funnel activity remains positive, but if you recall, we do have a pretty tough comp here in the third quarter in MPT. In HST industrial, demand remains overall very strong. I am now moving on to our final segment, diversified. I am on slide seven. Q2 orders were up 21% overall, 18% organically. Dispensing did have an easy comp as we had a large project last year push the second half. But even if we exclude that, orders would have been up double digits for the quarter. Revenues were up 11% overall, 8% organically. Excluding restructuring expenses, adjusted operating margin of 28.1% increased 300 basis points. This was mainly attributable to significant volume upside, along with productivity. In dispensing North American and European markets remained strong and steady with increased orders and project activity. Emerging markets remained strong from across market growth and new product development penetration. In fire and safety, rescue is positive across the globe and we have project activity pick up in India, China and the Middle East. And our fire OEM and Muni business is steady. As I mentioned earlier, we are very excited to incorporate the recently purchased assets of Phantom Controls. And finally, margins continued to improve at both Akron Brass and AWG. They are ahead of expectations. At Band-It, last but not least, we have experienced a double-digit organic order and revenue growth, driven by share gains and overall strong demand across the globe. Let me now conclude with some additional details to our 2018 guidance for the quarter and for the year. I am on slide eight. In Q3, we are estimating EPS in the range of the $1.29 to $1.32 with organic revenue growth in the range of 6% to 7% and operating margin of 23%. The Q3 effective tax rate is expected be approximately 22.5% with estimated less than 1% topline headwind from FX based on the June 30 rates. Corporate costs are expected to be approximately $20 million. Turning to full year. We have increased our full-year EPS guidance to a range of $5.27 to $5.35. Full-year organic revenue growth is expected be approximately 7%, so a nice increase in organic revenue guidance as well. If you remember, we have guided before at 5% to 6%. Full-year operating margin is expected to be in the range of 22.5% and 23%. For FX, it's going to be 1% tailwind for the year, based on the June 30 rates, but we will have headwind in the back half that is worth about $0.06 to us. The full-year effective tax rate is going to be about 23%, but we will see what happens here with tax reform. Capital expenditures are anticipated to be around $45 million. Free we cash flow will remain strong at 110% of net income and corporate costs should be in the range of $76 million to $80 million, that's up around a little more than $2 million from the stamp tax that I mentioned before. Finally, our earnings guidance excludes any associated cost of future acquisitions or restructuring. With that, Brenda, let me turn it over to any questions people have.